Lupin has launched its Clobetasol Propionate Topical Solution USP, 0.05% having received an approval from the United States Food and Drug Administration (USFDA) earlier to market a generic version of Fougera Pharmaceuticals’ Temovate (clobetasol propionate) Scalp Application, 0.05%.
Lupin’s Clobetasol Propionate Topical Solution USP, 0.05% is an AT rated generic equivalent of Fougera Pharmaceuticals’ Temovate (clobetasol propionate) Scalp Application, 0.05%. It is indicated for short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp. Temovate Clobetasol Propionate Scalp Application had US sales of $64.1 million as per IMS MAT December 2016.
Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.
